{"id":11090,"date":"2026-04-28T13:55:08","date_gmt":"2026-04-28T13:55:08","guid":{"rendered":"https:\/\/cannabisindustryjournal.com\/?post_type=feature_article&amp;p=38757"},"modified":"2026-04-28T13:55:08","modified_gmt":"2026-04-28T13:55:08","slug":"engineering-consistency-inside-the-push-for-gmp-compliant-cannabis","status":"publish","type":"post","link":"https:\/\/cannitrol.com\/blog\/engineering-consistency-inside-the-push-for-gmp-compliant-cannabis\/","title":{"rendered":"Engineering Consistency: Inside the Push for GMP-Compliant\u00a0Cannabis"},"content":{"rendered":"<div id=\"wp_fb_like_button\" style=\"margin:5px 0 5px 5px;float:right;height:100px;\"><script src=\"http:\/\/connect.facebook.net\/en_US\/all.js#xfbml=1\"><\/script><fb:like href=\"https:\/\/cannitrol.com\/blog\/engineering-consistency-inside-the-push-for-gmp-compliant-cannabis\/\" send=\"true\" layout=\"standard\" width=\"450\" show_faces=\"false\" font=\"arial\" action=\"like\" colorscheme=\"light\"><\/fb:like><\/div><div><img src=\"https:\/\/cannitrol.com\/blog\/wp-content\/uploads\/2026\/04\/engineering-consistency-inside-the-push-for-gmp-compliant-cannabis.png\" class=\"ff-og-image-inserted\" \/><\/div>\n<p>As cannabis becomes a globally traded medical commodity, cGMP compliance is reshaping how it is grown, handled, and transported. For operators working with imported biomass, controlling contamination and ensuring consistency across supply chains has become a defining challenge. That challenge was a central focus at the International Cannabis Business Conference in Berlin, where a panel on Good Manufacturing Practices (GMP) examined how operators can meet the European Union\u2019s stringent standards for medical cannabis.<\/p>\n<p>Moderated by Constant Ma, CEO &amp; President of Cannactions Consulting Ltd., the session brought together cultivators, scientists, and technology providers to discuss contamination risk from cultivation through post-harvest processing and packaging.<\/p>\n<p>Unlike many agricultural commodities, cannabis presents a distinct compliance challenge. It is a biological product, inherently variable from batch to batch, and highly susceptible to microbial contamination. In medical markets, particularly in Europe,\u00a0variability must be tightly controlled.<\/p>\n<p>\u201cAll of this is super important because with GMP, we have to make sure that our products are consistent at all times,\u201d Ma said.\u00a0\u201cAnd we also have to make sure that it\u2019s safe for the patients that are using it.\u201d<\/p>\n<h4><strong>Where Contamination Risk Begins<\/strong><\/h4>\n<p>Panelists emphasized that contamination risk does not begin in processing. It starts in cultivation and carries through every stage of production.<\/p>\n<p>Matthieu van der Born, CEO &amp; Founder of Flower Power, is transitioning operations from Good Agricultural and Collection Practices (GACP) to GMP, pointing to labor-intensive processes such as hand-trimming as a source of risk. High personnel density increases touchpoints, while environmental systems must account for both plant material and human activity.<\/p>\n<p>Rui Soares, CEO of Paralab Green, stressed that early-stage decisions, including facility design, nutrients, and environmental controls, have lasting downstream impacts. \u201cIf you invest for quantity and not for quality, you have no future,\u201d he said, reinforcing a recurring theme: contamination is often the result of upstream compromises.<\/p>\n<h4><strong>The Critical Window: Post-Harvest<\/strong><\/h4>\n<p>The discussion turned to post-harvest handling, widely viewed as the most vulnerable phase for microbial growth. Ed Wells, Vice President of Sales at Cannatrol, framed the issue as a risk management matter. \u201cAt the heart of GMP, you are identifying risk, then you\u2019ve got to mitigate that risk so you have safe and predictable outcomes,\u201d he said.<\/p>\n<p>Once cannabis is harvested, microbial populations can expand rapidly if environmental conditions are not tightly controlled. The key variable is water activity: the moisture available to support microbial growth. Until the product reaches shelf stability, microbial load can continue to increase.<\/p>\n<p>\u201cThe name of the game is to provide an environment where that flower becomes shelf stable as soon as possible,\u201d Wells said. \u201cThat is your window of risk.\u201d<\/p>\n<p>That window is shaped by both process design and operations. Traditional methods, such as hanging whole plants, can extend drying time and prolong exposure. More controlled approaches, such as reducing biomass earlier and optimizing environmental conditions, can shorten that timeline, though they may require greater coordination of labor.<\/p>\n<p>Joseph Edwards, Chief Scientist &amp; Vice President of Deconix, described post-harvest cannabis as a \u201cparasitic host relationship,\u201d where microbial organisms continue to thrive on plant material. Without precise control of humidity, temperature, and airflow, the risk of contamination escalates quickly.<\/p>\n<h4><strong>Decontamination vs. Prevention<\/strong><\/h4>\n<p>A central tension in GMP compliance is the role of decontamination.\u00a0While remediation technologies are widely used, panelists agreed they should not be the primary line of defense.\u00a0Soares emphasized that microbial reduction should not be treated as a default step, but as a corrective measure when prevention fails, aligning with GMP principles that prioritize process control over downstream intervention.<\/p>\n<p>Still, decontamination remains necessary when microbial levels exceed thresholds. George Terry, Executive Vice President of Rad Source, noted that technologies such as X-ray-based systems can help ensure compliance, particularly for export into regulated markets. The broader takeaway is that GMP compliance relies on layered controls: facility design, environmental management, operational discipline, and, when needed, remediation.<\/p>\n<h4><strong>Planning, Cost, and Differentiation<\/strong><\/h4>\n<p>The panel also addressed the economic realities of GMP compliance. Building a compliant facility requires significant upfront investment, and poor planning can lead to costly retrofits.<\/p>\n<p>\u201cDon\u2019t set yourself up to have to spend good money after bad,\u201d Wells said,\u00a0advising operators to\u00a0prioritize systems that improve both product quality and operational efficiency.<\/p>\n<p>\u00a0As markets mature and pricing compresses, differentiation becomes critical. Consistency\u2014delivering the same product profile batch after batch\u2014was repeatedly cited as a competitive advantage, particularly in medical markets where patients rely on predictable outcomes.<\/p>\n<p>Panelists drew comparisons to pharmaceuticals and consumer goods, where consistency is non-negotiable. Variability in a medical product would be unacceptable.<\/p>\n<h4><strong>A Maturing Standard<\/strong><\/h4>\n<p>The discussion reflects an industry in transition. While GMP standards are well established in pharmaceuticals, their application to cannabis is still evolving, shaped by regulation and the biological complexity of the plant.<\/p>\n<p>What is clear is that expectations are rising, especially in Europe. As more markets adopt GMP requirements, operators must approach cultivation, processing, and quality assurance as an integrated system rather than discrete steps.<\/p>\n<p>For medical cannabis, patient safety, product consistency, and regulatory compliance are no longer aspirational. They are baseline requirements. And as the panel made clear, meeting those requirements begins long before the product reaches the patient.<\/p>\n<div class=\"sharedaddy sd-sharing-enabled\">\n<div class=\"robots-nocontent sd-block sd-social sd-social-icon-text sd-sharing\">\n<h3 class=\"sd-title\">Share this:<\/h3>\n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>As cannabis becomes a globally traded medical commodity, cGMP compliance is reshaping how it is grown, handled, and transported. For operators working with imported biomass, controlling contamination and ensuring consistency across supply chains has become a defining challenge. That challenge was a central focus at the International Cannabis Business Conference in Berlin, where a panel [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[8509,1873,11069,10851,5763,9,8504,10819,1,3,61,1736],"tags":[8535,4441,11070,10852,5771,8530,10820],"_links":{"self":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts\/11090"}],"collection":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/comments?post=11090"}],"version-history":[{"count":0,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts\/11090\/revisions"}],"wp:attachment":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/media?parent=11090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/categories?post=11090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/tags?post=11090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}